COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Safety Study of Bone Marrow Cell Concentrate Prepared Using the Magellan System to Treat Critical Limb Ischemia (CLI) (CLI)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01386216
Recruitment Status : Completed
First Posted : July 1, 2011
Last Update Posted : January 24, 2017
Information provided by (Responsible Party):
Arteriocyte, Inc.

Brief Summary:
The purpose of this study is to evaluate the safety of administration of marrow-derived autologous hematopoietic stem cells (HSC) concentrate and platelet-rich plasma (PRP) gel for the treatment of Critical Limb Ischemia (CLI).

Condition or disease Intervention/treatment Phase
Critical Limb Ischemia (CLI) Peripheral Vascular Disease (PVD) Device: Magellan® Phase 1

Detailed Description:

Critical limb ischemia (CLI) continues to be an important cause of atherosclerotic morbidity and mortality despite conventional therapies. Modulation of angiogenesis is a promising alternative to surgical revascularization. Trials of isolated angiogenic growth factor therapies using recombinant proteins or gene transfer have been conducted, but with disappointing results because it is unlikely that a single angiogenic factor is solely or even primarily responsible for angiogenesis. Emerging stem cell therapies represent a new approach to the modulation of angiogenesis. Pluripotent hematopoietic stem cells (HSC) hold promise because they can reproduce a pro-angiogenic milieu in the ischemic limb rather than upregulate a single angiogenic factor.

For this CLI study, the Magellan® System is utilized for the preparation of autologous cell concentrate at the point of care. The bone marrow aspirate is obtained from the patient and concentrated with the cell concentration kit, and delivered intramuscularly to the affected limb for the treatment of impaired ischemic tissue in order to improve perfusion, reduce pain and revascularize tissues in patients who have inadequate tissue blood flow, prohibitive medical comorbidities, or failed previous treatments for revascularization for the prevention of amputation.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 18 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase I, Non-Randomized, Feasibility Study for the Use of Bone Marrow Cell Concentrate Prepared Using the Magellan System for the Treatment of Critical Limb Ischemia
Study Start Date : April 2011
Actual Primary Completion Date : April 2016
Actual Study Completion Date : December 2016

Arm Intervention/treatment
Experimental: Bone Marrow Cell Concentrate
Bone Marrow Cell Concentrate Prepared Using the Magellan System
Device: Magellan®
Autologous Bone Marrow Cell Concentrate Prepared Using the Magellan System to be injected into the ischemic muscle tissue at 0.5 cc/injection for a total of 12-20 cc.
Other Name: autologous cell concentrate

Primary Outcome Measures :
  1. Time to treatment failure or death [ Time Frame: Baseline - 12 months ]
    Treatment failure is defined as major amputation

Secondary Outcome Measures :
  1. Perfusion and Quality of Life measurements [ Time Frame: Baseline - 12 months ]
    • Perfusion rate in treated tissue by measure of ankle-brachial index (ABI)
    • Perfusion rate in treated tissue by transcutaneous PO2 (TcPO2)
    • Perfusion rate in treated tissue by skin perfusion pressure (SPP)
    • Pain intensity using Visual Analogue Scale (VAS)
    • Quality of Life (QoL) by questionnaire

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 85 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Is able to provide written informed consent prior to study entry
  • Is male or female, 18 - 85 years of age
  • CLI with rest pain, tissue loss, or gangrene
  • No option for revascularization as a result of one of the following:

    • failed previous revascularization, such as recurrent instant restenosis or graft occlusion.
    • inadequate target vessels as determined by baseline CTA/angiogram at the time of enrollment.
    • or prohibitive medical comorbidities such as high risk cardiovascular or pulmonary disease which would restrict operative procedures
    • Final determination of no option for revascularization will be made by a vascular surgeon not associated with the clinical trial.
  • ABI less than 0.7, ankle pressure < 50 mmHg, or toe pressure < 30 mmHg.
  • TcPO2 < 40 mmHg
  • SPP < 35 mmHg
  • Female subjects must be of non childbearing potential (defined as postmenopausal for at least 1 year or surgically sterile [bilateral tubal ligation, bilateral oophorectomy or hysterectomy]) or must be using adequate contraception (practicing one of the following methods of birth control):

    • Total abstinence from sexual intercourse (minimum of one complete menstrual cycle before study entry),
    • A partner who is physically unable to impregnate the subject (e.g., vasectomized)
    • Contraceptives (oral, parenteral, or transdermal) for 3 consecutive months prior to patient's cell concentrate administration,
    • Intrauterine device (IUD), or
    • Double barrier method (condoms, sponge, diaphragm, or vaginal ring with spermicidal jellies or cream)
  • If female is of childbearing potential, subject must have a negative serum pregnancy test at screening
  • Confirmation of age-appropriate cancer screening consistent with the American Cancer Society guidelines

Exclusion Criteria:

  • Patients with vascular lesions amenable to percutaneous intervention or where surgical bypass is indicated.
  • Any contraindication to stem cell or platelet-rich plasma therapy.
  • Isolated aorto-iliac stenoses or occlusions without infra-inguinal disease.
  • Pregnancy
  • Hemoglobin A1c >10 % on day of enrollment.
  • Have an active malignancy or have undergone treatment for a malignancy in the preceding 5 years, with the exception of successful treatment of non-melanoma skin cancer.
  • Stage 4 or greater chronic kidney disease (eGFR < 30 ml/min, MDRD estimate)
  • Hemoglobin < 10 g/dl.
  • Thrombocytopenia < 100,000 platelets/µL.
  • Unwilling or unable to comply with follow-up visits.
  • Proliferative retinopathy as determined by baseline retinal exam.
  • Is unable to refrain from nicotine, caffeine and alcohol for a period beginning 24 hours prior to the treatment visit
  • Has received an investigational medication or other study trial participation within 30 days prior to the Treatment Visit

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01386216

Layout table for location information
United States, Ohio
The Ohio State University Medical Center
Columbus, Ohio, United States, 43210
Sponsors and Collaborators
Arteriocyte, Inc.
Layout table for investigator information
Principal Investigator: Michael Go, MD Ohio State University
Layout table for additonal information
Responsible Party: Arteriocyte, Inc. Identifier: NCT01386216    
Other Study ID Numbers: ART 10-001
First Posted: July 1, 2011    Key Record Dates
Last Update Posted: January 24, 2017
Last Verified: January 2017
Keywords provided by Arteriocyte, Inc.:
Critical limb ischemia
Peripheral vascular disease
platelet-rich plasma
Additional relevant MeSH terms:
Layout table for MeSH terms
Vascular Diseases
Peripheral Vascular Diseases
Peripheral Arterial Disease
Pathologic Processes
Cardiovascular Diseases
Arterial Occlusive Diseases